News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2021

26 March, 2021 Dr Thomas Lönngren nominated as new Chairman of the Board at Egetis Therapeutics News Corporate Information Nomination Committee English Regulatory MAR IR Optional
17 February, 2021 Egetis Therapeutics presents the fourth quarter and the year-end report 2020 News English Regulatory Listing Regulation Report Interim Yearend IR Optional
15 February, 2021 Egetis appoints Dr Kristina Sjöblom Nygren as new CMO News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
10 February, 2021 Aladote presented as a novel emerging treatment of paracetamol overdose at two scientific conferences. News Corporate Action Other English IR Optional
20 January, 2021 Peder Walberg appointed as interim Chief Medical Officer News Corporate Information Staff change English Regulatory Listing Regulation IR Optional

2020

30 December, 2020 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
22 December, 2020 Nomination Committee appointed for the 2021 Annual General Meeting in Egetis Therapeutics News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
17 December, 2020 PledPharma changes its name to Egetis Therapeutics with focus on late stage orphan drug development News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
15 December, 2020 Results from the prematurely closed PledOx POLAR program News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
11 December, 2020 Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 11 December 2020 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
7 December, 2020 First patient dosed in Phase IIb/III study with Emcitate® News Corporate Information Other Corporate Information English IR Optional
30 November, 2020 Change in the number of shares and votes in PledPharma News Corporate Action Shares Issuance English Regulatory LHFI IR Optional
25 November, 2020 PledPharma raises SEK 250 million in oversubscribed rights issue and utilized overallotment option News Corporate Action Shares Issuance English Regulatory MAR IR Optional
23 November, 2020 Clarification regarding ownership changes in PledPharma News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
18 November, 2020 FDA grants Rare Pediatric Disease designation to Emcitate® News Corporate Action Other English IR Optional
12 November, 2020 PledPharma publishes a supplement to the prospectus News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
11 November, 2020 Interim Report January 1-September 30, 2020 News English Regulatory MAR Report Interim Q3 IR Optional
10 November, 2020 NOTICE TO ATTEND EXTRAORDINARY GENERAL MEETING IN PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
6 November, 2020 Henrik Krook appointed VP Commercial Operations at PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
5 November, 2020 PledPharma publishes prospectus and updated financial information in connection with fully guaranteed rights issue and the admission to trading of shares News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
3 November, 2020 PledPharma completes the acquisition of Rare Thyroid Therapeutics News Corporate Action M&A English IR Optional
28 October, 2020 Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 28 October 2020 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
20 October, 2020 Nomination Committee appointed for the 2021 Annual General Meeting in PledPharma News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
14 October, 2020 Design of pivotal Phase IIb/III study for Aladote® finalized after completed interactions with FDA, EMA and MHRA News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote
5 October, 2020 Notice of Extraordinary general meeting in PledPharma AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional

Calendar and upcoming reports

August 22, 2024
Interim Report Q2 2024 (7:00am CEST)

September 19, 2024
Pareto Annual Healthcare Conference

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com